HIV Drugs Market Size, Share, Trends, Growth Outlook

HIV Drugs Market is estimated to increase at a growth rate of 6.5% CAGR over the forecast period from 2024 to 2030.

The global HIV Drugs Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Medication Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors, Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors), By Distribution Channel (Hospital Pharmacies, Drugs stores and retail pharmacies, Online pharmacies).

An Introduction to HIV Drugs Market in 2024

The HIV Drugs Market encompasses pharmaceutical therapies, antiretroviral medications, and combination drug regimens used in the treatment and management of HIV (Human Immunodeficiency Virus) infection. This market includes nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, and entry inhibitors designed to suppress viral replication, improve immune function, and reduce HIV-related complications. Advances in HIV drug development focus on long-acting formulations, drug resistance management, combination therapies, and personalized treatment approaches to enhance patient outcomes and achieve viral suppression.

HIV Drugs Market Competitive Landscape

The global HIV Drugs Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, HIV Drugs Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the HIV Drugs Industry include- Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd, Cipla Ltd, Emcure Pharmaceuticals Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Hetero Labs Ltd, Johnson and Johnson Services Inc, Lupin Ltd, Macleods Pharmaceuticals Ltd, Merck and Co. Inc, Strides Pharma Science Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Viatris Inc.

HIV Drugs Market Trend: Advancements in Antiretroviral Therapy (ART)

A significant trend in the HIV Drugs market is the continual advancements in antiretroviral therapy (ART) for the management of HIV infection. ART plays a crucial role in suppressing viral replication, preserving immune function, and improving the quality of life for individuals living with HIV. Recent developments include the introduction of new drug classes, such as integrase inhibitors and entry inhibitors, as well as fixed-dose combination therapies that simplify treatment regimens and improve adherence. Additionally, long-acting formulations, including injectable and implantable drugs, offer alternatives to daily oral therapy, enhancing convenience and treatment adherence. This trend underscores the ongoing innovation in HIV drug development, aiming to achieve better treatment outcomes, reduce treatment-related toxicity, and address emerging challenges such as drug resistance and comorbidities.

HIV Drugs Market Driver: Global HIV/AIDS Epidemiology and Treatment Scale-Up

The primary driver for the HIV Drugs market is the global HIV/AIDS epidemic and the scale-up of HIV treatment initiatives aimed at expanding access to antiretroviral therapy (ART) for people living with HIV. Despite significant progress in HIV prevention and treatment, millions of individuals worldwide still require access to life-saving HIV medications. Efforts such as the United Nations' 90-90-90 targets, which aim to diagnose 90% of all HIV-positive individuals, provide ART to 90% of those diagnosed, and achieve viral suppression in 90% of those treated by 2020, drive the demand for HIV drugs. Additionally, the increasing adoption of pre-exposure prophylaxis (PrEP) as a preventive measure among high-risk populations further expands the market for HIV medications. The scale-up of HIV treatment programs, coupled with the introduction of new treatment guidelines and recommendations, supports market growth and innovation in HIV drug development.

HIV Drugs Market Opportunity: Focus on Long-Acting and Novel Therapeutic Modalities

An emerging opportunity in the HIV Drugs market lies in the development of long-acting and novel therapeutic modalities to address the evolving needs of HIV treatment and prevention. Long-acting antiretroviral agents, such as injectable formulations and extended-release implants, offer potential benefits in terms of improved treatment adherence, reduced pill burden, and enhanced viral suppression. Additionally, novel therapeutic approaches, including gene editing technologies such as CRISPR/Cas9, therapeutic vaccines, and immune-based therapies, hold promise for achieving functional cure or sustained remission in HIV infection. Collaborative research efforts between pharmaceutical companies, academic institutions, and government agencies could accelerate the development and commercialization of long-acting and novel HIV therapeutics, offering new treatment options for individuals living with HIV and contributing to global efforts towards ending the HIV/AIDS pandemic.

HIV Drugs Market Share Analysis: HIV Integrase Strand Transfer Inhibitors is the fastest growing market segment over the forecast period to 2030

HIV integrase strand transfer inhibitors, including medications such as Isentress/Isentress HD, Tivicay, Apretude, and Juluca, are experiencing significant growth in the treatment of HIV. This growth is primarily due to the effectiveness of integrase inhibitors in suppressing viral replication and achieving durable viral suppression with fewer side effects compared to older antiretroviral drug classes. Integrase inhibitors work by blocking the action of the HIV integrase enzyme, preventing the integration of viral DNA into the host cell genome. Their potent antiviral activity and favorable tolerability profile have made them a preferred choice for initial and maintenance therapy in both treatment-naive and treatment-experienced HIV patients. Moreover, the development of newer integrase inhibitors with improved pharmacokinetic profiles and once-daily dosing regimens has further contributed to their growing popularity and adoption in clinical practice. As a result, HIV integrase strand transfer inhibitors represent a rapidly expanding class of medications in the treatment of HIV, offering patients effective and well-tolerated options for long-term viral suppression.

HIV Drugs Market Segmentation

By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

HIV Drugs Companies

Aspen Pharmacare Holdings Ltd
Aurobindo Pharma Ltd
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Cadila Pharmaceuticals Ltd
Cipla Ltd
Emcure Pharmaceuticals Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Hetero Labs Ltd
Johnson and Johnson Services Inc
Lupin Ltd
Macleods Pharmaceuticals Ltd
Merck and Co. Inc
Strides Pharma Science Ltd
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Viatris Inc
* List not Exhaustive

Reasons to Buy the HIV Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the HIV Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the HIV Drugs Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 HIV Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global HIV Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 HIV Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 HIV Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 HIV Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 HIV Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of HIV Drugs Industry
4.2 Key Market Trends in HIV Drugs Industry
4.3 Potential Opportunities in HIV Drugs Industry
4.4 Key Challenges in HIV Drugs Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global HIV Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global HIV Drugs Market Outlook by Segments
7.1 HIV Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
8 North America HIV Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America HIV Drugs Markets in 2024
8.2 North America HIV Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America HIV Drugs Market size Outlook by Segments, 2021-2030
By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
9 Europe HIV Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe HIV Drugs Markets in 2024
9.2 Europe HIV Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe HIV Drugs Market Size Outlook by Segments, 2021-2030
By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
10 Asia Pacific HIV Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific HIV Drugs Markets in 2024
10.2 Asia Pacific HIV Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific HIV Drugs Market size Outlook by Segments, 2021-2030
By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
11 South America HIV Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America HIV Drugs Markets in 2024
11.2 South America HIV Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America HIV Drugs Market size Outlook by Segments, 2021-2030
By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
12 Middle East and Africa HIV Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa HIV Drugs Markets in 2024
12.2 Middle East and Africa HIV Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa HIV Drugs Market size Outlook by Segments, 2021-2030
By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Aspen Pharmacare Holdings Ltd
Aurobindo Pharma Ltd
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Cadila Pharmaceuticals Ltd
Cipla Ltd
Emcure Pharmaceuticals Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Hetero Labs Ltd
Johnson and Johnson Services Inc
Lupin Ltd
Macleods Pharmaceuticals Ltd
Merck and Co. Inc
Strides Pharma Science Ltd
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Viatris Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Medication Class
Multi-Class Combination Drugs
-Atripla
-Complera
-Prezcobix
-Stribild
-Genvoya
-Odefsey
-Symtuza
-Triumeq
-Descovy
-Dovato
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-Emtriva
-Epivir
-Epzicom/Kivexa
-Truvada
-Biktarvy
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Edurant
-Others
Protease Inhibitors
-ptivus
-Kaletra
-Lexiva/ Telzir
-Norvir
-Viracept
-Others
Entry Inhibitors
-Selzentry
-Fuzeon
-Rukobia
HIV Integrase Strand Transfer Inhibitors
-Isentress/Isentress HD
-Tivicay
-Apretude
-Juluca
By Distribution Channel
Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies